Related Experiment Video
Updated: Jul 17, 2026
10:04
Local Application of Drugs to Study Nicotinic Acetylcholine Receptor Function in Mouse Brain Slices
Published on: October 29, 2012
Non-nicotinic therapies for smoking cessation
Eric C K Siu1, Rachel F Tyndale
1Center for Addiction & Mental Health and Department of Pharmacology, University of Toronto, Toronto, Canada. eric.siu@utoronto.ca
Annual Review of Pharmacology and Toxicology
|January 11, 2007
Summary
Smoking cessation therapies aim to reduce health risks and improve life quality. Emerging treatments like nicotine vaccines and new medications offer more options for smokers seeking to quit.
Area of Science:
- Pharmacology
- Public Health
- Addiction Medicine
Background:
- Cigarette smoking is a leading cause of preventable diseases.
- Smoking cessation improves health and quality of life.
- Current first-line therapies include nicotine replacement and bupropion.
Purpose of the Study:
- To review current and emerging therapies for smoking cessation.
- To highlight new pharmacologic and vaccine-based approaches.
Main Methods:
- Literature review of smoking cessation pharmacotherapies.
- Discussion of FDA-approved and investigational treatments.
Main Results:
- Varenicline is an FDA-approved nicotinic receptor partial agonist.
- Nicotine vaccines are under development.
- Clonidine and nortriptyline show efficacy but have side effects.
- Investigational drugs include rimonabant, mecamylamine, MAOIs, and D3 antagonists.
- Nicotine metabolism inhibitors are promising.
Conclusions:
- New therapeutic products are emerging for smoking cessation.
- These advancements will provide additional options for smokers.
- The future of smoking cessation includes diverse pharmacologic and immunologic strategies.
Related Concept Videos
01:23Drugs Acting on Autonomic Ganglia: Stimulants
Ganglionic stimulants activate NM nicotinic receptors in autonomic ganglia, falling into two categories: nicotine mimetics [e.g., lobeline, dimethylpiperazine, tetramethylammonium] and muscarinic receptor agonists [e.g., muscarine, methacholine]. The first category's action is rapid and blocked by nicotinic receptor antagonists, while the second category's action is delayed and blocked by atropine-like agents. Nicotine, an alkaloid, affects the heart rate by stimulating sympathetic or...
01:27CNS Depressants: Alcohol and Nicotine
Ethanol, a clear colorless alcohol, has been consumed by humans for millennia, but its effects on the body are far from benign. At lower doses, it induces decreased inhibitions and loquaciousness, leading to its social appeal. However, it can cause severe consequences at higher doses, such as coma and respiratory depression, due to its zero-order elimination kinetics. Chronic ethanol abuse wreaks havoc on multiple organ systems, particularly the CNS and the liver. Abrupt cessation of ethanol...
01:15Cholinergic Receptors: Nicotinic
Nicotinic receptors are ligand-gated ion channels that are activated by acetylcholine and nicotine. Upon activation, they cause a rapid increase in the permeability of cells to K+, Na+, and Ca2+, followed by depolarization and excitation. They are in the autonomic ganglia, skeletal neuromuscular junction, CNS, and adrenal medulla.
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
There are two types of nicotinic receptors: neuromuscular (NM/NM/N1) and neuronal (NN/NN/N2). The two families differ based on their location and selectivity to...
01:22Direct-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
Cholinergic agonists or cholinomimetics mimic the action of acetylcholine to stimulate the parasympathetic nervous system. They are categorized into direct-acting and indirect-acting agents. The direct-acting cholinergic drugs induce the parasympathetic response by directly binding to the muscarinic or nicotine receptors. In comparison, the indirect-acting cholinergic drugs prevent acetylcholine hydrolysis, indirectly contributing to the extended parasympathetic response.
The direct-acting...
The direct-acting...
01:11Direct-Acting Cholinergic Agonists: Therapeutic Uses
Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
01:28Drugs Acting on Autonomic Ganglia: Blockers
Ganglionic blockers inhibit autonomic activity by blocking nicotinic receptors in the autonomic ganglia, suppressing impulse transmission. These blockers lack selectivity between sympathetic and parasympathetic ganglia and are ineffective as neuromuscular junction antagonists. They can be categorized into two groups: